Indian pharma firms likely to dodge immediate impact of Trump's tariff

Trump's 100% tariffs on branded drugs will spare Indian generics, though analysts see exposure for Sun Pharma, Biocon and Aurobindo, with Jubilant Pharmova set to benefit

Indian drugmakers are unlikely to be affected by American President Donald Trump’s decision to impose a 100 per cent tariff on imported branded or patented pharmaceuticals, as they largely supply generic drugs to the United States. However, Sun Pharma, Biocon, Aurobindo Pharma, and other Indian majors in the US branded drugs market may face some “negative impact”, according to analysts.

 

The Nifty Pharma index fell 2.14 per cent on Friday after Trump announced the tariff on Truth Social. He said pharmaceutical companies that have either “broken ground” or are in the construction phase of their manufacturing plants in the US